ANAB AnaptysBio Corp: Forward P/S Multiple
AnaptysBio, Inc. (ANAB) is shifting toward scaling its own immunological drugs, moving away from a platform development model. This forward P/S chart reflects market expectations, where 6.00 represents the latest metric reading. However, sector volatility and reliance on partner payments create risks, which are further amplified by geopolitical disruptions in biomaterial supply chains and delays in international trials.
Financial and market metric breakdowns for AnaptysBio Inc. (ANAB)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
ANAB - Company Net Income|Projected Future Earnings AnaptysBio, Inc.|ANAB - Business Payback Period|Future Price to Earnings AnaptysBio Corp|ANAB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio AnaptysBio Inc.|ANAB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) AnaptysBio|ANAB - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months anaptysbio.com|ANAB - Earnings per share growth this year|Earnings growth forecast for next year AnaptysBio, Inc.
- sales and revenue indicators:
General company analysis:AnaptysBio (ANAB)
Utilizing external partners for clinical testing and manufacturing allows AnaptysBio, Inc. (ANAB) to optimize costs when bringing innovations to market. By analyzing the forward P/S dynamics, an investor can see the correlation between current capitalization and expected revenue during the intervals between reports. This ratio measures the market's revaluation of future sales, revealing the gap between the share price and the actual productivity of the business. This helps determine the risk of inflated expectations regarding the cost of capital.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Forward P/S Multiple Grifols SA|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX: Future Price to Revenue|Aurinia Pharmaceuticals - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BCRX (biocryst.com)|VERA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|ABCL - Market Cap to Expected Sales Ratio|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PGEN|Forward P/S Multiple PHAR|Market Cap to Expected Sales Ratio Nektar Therapeutics Inc|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|Zenas Corp (ZBIO) - Market Cap to Future Revenue Ratio|IMNM: Forward Price-to-Revenue Multiple|Forward Price to Sales GOSS (gossamerbio.com)|KALV: Forward P/S Multiple|SEPN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Market Cap to Projected Revenue SVRA (Savara Pharma)|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple astriatx.com ATXS|enGene - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio RAPT Therapeutics Inc. (RAPT)|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TLSA|CABA (Cabaletta Bio) - Forward P/S Multiple|Forward P/S Multiple Ventyx Biosciences Inc.|Forward P/S Multiple THTX|Price-to-Projected Revenue Ratio AVTX (Avalo Therapeutics Inc)|Price-to-Projected Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN (agenusbio.com) - Future Price to Revenue|Climb Bio - Forward P/S Multiple|Forward Price to Sales ZURA (Zura Bio Ltd)|ATYR: Forward P/S Multiple|Adagene Inc. (ADAG) - Forward P/S Multiple|Price-to-Projected Revenue Ratio ImageneBio|STTK: Forward Price to Sales|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|Forward Price-to-Revenue Multiple connectbiopharm.com CNTB|Forward P/S Multiple IMUX (Immunic)|Forward P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX: Forward Price-to-Revenue Multiple|Forward Price to Sales XFOR (x4pharma.com)|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio INmune Bio Corp|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|Forward Price-to-Revenue Multiple sabbiotherapeutics.com SABS|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Price-to-Projected Revenue Ratio|GOVX (GeoVax Corp) - Market Cap to Projected Revenue|EDSA: Forward P/S Multiple|Market Cap to Future Revenue Ratio ibioinc.com (IBIO)|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|Forward P/S Multiple XTL Biopharmaceuticals Ltd|Price-to-Projected Revenue Ratio Bolt Biotherapeutics (BOLT)|hcwbiologics.com - Market Cap to Projected Revenue|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|Forward P/S Multiple AIM ImmunoTech, Inc. AIM|ADTX - Price-to-Projected Revenue Ratio|Future Price to Revenue GRI|XRTX (XORTX) - Forward Price-to-Revenue Multiple|HIND: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple REVB|Market Cap to Future Revenue Ratio indaptusrx.com INDP|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|Market Cap to Expected Sales Ratio calcimedica.com|Forward P/S Multiple AFMD (Affimed N.V.)|Allakos Inc - Price-to-Projected Revenue Ratio|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Ocean Biomedical Inc (OCEA)|Forward Price-to-Revenue Multiple TCBP|THRD: Forward Price to Sales
